论文部分内容阅读
Napo制药公司于2007-12-07宣布,该公司授权的Glenmark制药公司已经在印度的2个试验点展开crofelemer治疗急性传染性腹泻的安慰剂对照Ⅱ期临床试验,并期望该项临床试验在6个月内完成。
Napo Pharmaceuticals announced on December 12, 2007 that its licensed Glenmark Pharmaceuticals Company has started a placebo-controlled Phase II clinical trial of crofelemer in acute infectious diarrhea at two pilot sites in India and expects the clinical trial to be conducted at 6 Completed within a month.